Registration number: 08136359

JCB Med Limited

Contents

Balance Sheet	1 to 2
Notes to the Unaudited Financial Statements	3 to 8

JCB Med Limited

Balance Sheet
31 July 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	4	52	206
Current assets
Stocks	5	90,293	102,793
Creditors: Amounts falling due within one year	6	(207,868)	(184,671)
Net current liabilities		(117,575)	(81,878)
Total assets less current liabilities		(117,523)	(81,672)
Creditors: Amounts falling due after more than one year	6	(30,635)	(44,430)
Provisions for liabilities		(150,000)	(150,000)
Net liabilities		(298,158)	(276,102)
Capital and reserves
Called up share capital		5	5
Retained earnings		(298,163)	(276,107)
Shareholders' deficit		(298,158)	(276,102)

For the financial year ending 31 July 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•	The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The Director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

JCB Med Limited

Balance Sheet
31 July 2025

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the Director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 28 April 2026
 

......................................... Dr J C Buteriteri Director

Company Registration Number: 08136359

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

1	General information

The Company is a private company limited by share capital, incorporated in England.

The Company registration number is 08136359

The address of its registered office is:
16 New Oak Close
Failsworth
Manchester
M35 9XD
England

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis. The director has confirmed that he is in a position financially to be able to support the company with regard to the provisions that may become payable. The director has reviewed forecasts for a period of 12 months from the balance sheet date and in his opinion the company is a going concern.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities.

The company recognises revenue when: the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

Government grants

Government grants in respect of capital expenditure are credited to a deferred income account and are released to profit over the expected useful lives of the relevant assets by equal annual instalments. Grants of a revenue nature are credited to income so as to match them with the expenditure to which they relate.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office equipment	25% straight line
Fixture and fittings	25% straight line
Plant and machinery	25% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Work in progress

Work in progress is valued on the basis of direct costs plus attributable overheads based on normal level of activity. Provision is made for any foreseeable losses where appropriate. No element of profit is included in the valuation of work in progress.

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Provisions

Provisions are recognised when the Company has an obligation at the reporting date as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Recognition and measurement
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
 

3	Staff numbers

The average number of persons employed by the Company (including the Director) during the year, was 2 (2024 - 2).

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

4	Tangible assets

	Fixtures and fittings £	Plant and machinery £	Office equipment £	Total £
Cost or valuation
At 1 August 2024	1,356	54,002	4,547	59,905
At 31 July 2025	1,356	54,002	4,547	59,905
Depreciation
At 1 August 2024	1,356	54,002	4,341	59,699
Charge for the year	-	-	154	154
At 31 July 2025	1,356	54,002	4,495	59,853
Carrying amount
At 31 July 2025	-	-	52	52
At 31 July 2024	-	-	206	206

5

Stocks

	2025 £	2024 £
Work in progress	90,293	102,793

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

6

Creditors

Creditors: amounts falling due within one year

	Note	2025 £	2024 £
Due within one year
Loans and borrowings	7	35,893	27,015
Accruals and deferred income		15,582	24,551
Other creditors		156,393	133,105
		207,868	184,671

Creditors: amounts falling due after more than one year

	Note	2025 £	2024 £
Due after one year
Loans and borrowings	7	30,635	44,430

7	Loans and borrowings

Non-current loans and borrowings

	2025 £	2024 £
Bank borrowings	30,635	44,430

Current loans and borrowings

	2025 £	2024 £
Bank borrowings	21,094	11,458
Bank overdrafts	14,799	15,557
	35,893	27,015

JCB Med Limited

Notes to the Unaudited Financial Statements
Year Ended 31 July 2025

8	Related party transactions

Summary of transactions with other related parties

Other related party transactions

Loans from related parties

2025	Key management £	Total £
At start of period	100,266	100,266
Advanced	38,998	38,998
Repaid	(15,710)	(15,710)
At end of period	123,554	123,554

2024	Key management £	Total £
At start of period	79,358	79,358
Advanced	31,710	31,710
Repaid	(10,802)	(10,802)
At end of period	100,266	100,266